Phytochemical screening of Solanum xanthocarpum and its xanthine oxidase inhibitory activity

Abstract

Pharmacological features and chemical compounds derived from Solanum xanthocarpum (S. xanthocarpum) are often investigated. S. xanthocarpum has been widely used to treat a variety of ailments as traditional medicine. Different parts of the plant are being studied to find more new uses for the herb. Xanthine oxidase inhibition is important in many vascular, renal, and bone disorders as this super enzyme causes an increase in the uric acid formation and oxidative stress. With this perspective and current literature, further studies are required to be conducted to highlight new features that may be derived from the plant. This study aimed to explore the fruits of S. xanthocarpum for their phytochemical constituents and their xanthine oxidase inhibitory activity. Fruits from S. xanthocarpum were identified and collected. We performed alcoholic extraction in the Soxhlet apparatus and fractionation using column chromatography. Furthermore, we analyzed phytochemical properties using fingerprinting chromatography, NMR (Nuclear magnetic resonance), mass-spectrometry (MS), ultraviolet (UV), and infrared (IR) spectroscopy. The NMR spectrum revealed new chemical moieties which were validated using MS. Later on, we conducted bioassays for xanthine oxidase Inhibitory activity on individual fractions. Three new chemical compounds were discovered (Eicosa -11, 14-dienoic acid, Docosa-7, 10, 13, 16, 19-pentanoic acid, and Glyceryl Tri Palmitoleate). These compounds were fatty acids in nature. Bioassay results obtained were positive and encouraging. Our study findings provide evidence of new chemical compounds that can be derived from S. xanthocarpum and can be used to treat renal diseases and gout by inhibiting excessive enzyme catalyzation of xanthine oxidase. The results suggest S. xanthocarpum as a possible candidate for a new therapeutic approach.

References

1. Argôlo AC, Charlwood BV, Pletsch M. The regulation of solasodine production by Agrobacterium rhizogenes-transformed roots of Solanum aviculare. Planta Med 2000; 66(5): 448-451.
2. Sen S, Chakraborty R. Revival, modernization and integration of Indian traditional herbal medicine in clinical practice: Importance, challenges and future. Journal of Traditional and Complementary Medicine. 2016; 1-11.
3. Tagbota S, Townson S. Antiparasitic properties of medicine and other natural occurring products. Adv. Parasitol.2001; 50: 199-205.
4. Mathur, R.; Velpandian, T. Medicinal plant-based health products: Where is the medicinal constituent? Indian J. Pharmacol. 2009, 41, 205.
5. Cahill MG, Caprioli G, Vittori S, James KJ. Elucidation of the mass fragmentation pathways of potato glycoalkaloids and aglycons using Orbitrap mass spectrometry. J Mass Spectrom 2010; 45(9): 1019-1025.
6. Chang LC, Tsai TR, Wang JJ, Lin CN, Kuo KW. The rhamnose moiety of solamargine plays a crucial role in triggering cell death by apoptosis. Biochem Biophys Res Commun 1998; 242(1): 21-25. [28] Lin
7. Bhat MA, Ahmad S, Aslam J, Mujib A, Mahmooduzzfar. Salinity stress enhances production of solasodine in Solanum nigrum L. Chem Pharm Bull 2008; 56(1): 17-21.
8. Bhatnagar P, Bhatnagar M, Nath AK, Sharma DR. Production of solasodine by Solanum laciniatum using plant tissue culture technique. Indian J Exp Biol 2004; 42(10): 1020-1023.
9. Parmar, S., Gangwal, A., Sheth, N., 2010. Solanum xanthocarpum (yellow berried night shade): a review. Der. Pharm. Lett. 2, 373–383.
10. Watt G (1893) A dictionary of the Economic products of India. W H Allen and Co. London Book Reviews.
11. Singh, K.V., Bansal, S.K., 2003. Larvicidal properties of a perennial herb Solanum xanthocarpum against vectors of malaria and dengue/DHF. Curr. Sci. 84, 749–751.
12. Paul AT, Vir S, Bhutani KK (2008) Liquid chromatography-mass spectrometry-based quantification of steroidal glycoalkaloids from Solanum xanthocarpum and the effect of different extraction methods on their content. J Chromatogr A 1208(1,2): 141-146.
13. Tekuri, S.K., Pasupuleti, S.K., Konidala, K.K., Amuru, S.R., Bassaiahgari, P., Pabbaraju, N., 2019. Phytochemical and pharmacological activities of Solanum surattense Burm. f.–A review. J. Appl. Pharmaceut. Sci. 9, 126–136.
14. Nithya, M., Ragavendran, C., Natarajan, D., 2018. Antibacterial and free radical scavenging activity of a medicinal plant Solanum xanthocarpum. Int. J. Food Prop. 21, 313–327.
15. Rini Hendriani1, Elin Yulinah Sukandar, KusnandarAnggadiredja, Sukrasno. In Vitro Evaluation of Xanthine Oxidase Inhibitory Activity of Selected Medicinal Plants. International Journal of Pharmaceutical and Clinical Research 2016; 8(4): 235-238
16. Bustanji Y, Hudaib M, Tawaha K, Mohammad M, Almasri I, Hamed S, et al. In vitro xanthine oxidase inhibition by selected Jordanian medicinal plants. Jordan J Pharm Sci. 2010
17. Mohammad MK, Almasri IM, Tawaha K, Issa A, Al-Nadaf A, Hudaib M, Alkhatib HS, Abu-Gharbieh E, Bustanji Y Pharm Biol. 2010 Dec; 48(12):1376-83.
18. Alali FQ, El-Elimat T, Li C, Qandil A, Alkofahi A, Tawaha K, Burgess JP, Nakanishi Y, Kroll DJ, Navarro HA, Falkinham JO 3rd, Wani MC, Oberlies NH J Nat Prod. 2005 Feb; 68(2):173-8.
19. P. Higgins, J. Dawson, and M. Walters, “The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease,” Cardiovascular Psychiatry and Neurology, vol. 2009, Article ID 282059, 9 pages, 2009.
20. W. S. Chang, Y. J. Lee, F. J. Lu, and H. C. Chiang, “Inhibitory effects of flavonoids on xanthine oxidase,” Anticancer Research, vol. 13, no. 6, pp. 2165–2170, 1993.
21. L. Costantino, A. Albasini, G. Rastelli, and S. Benvenuti, “Activity of polyphenolic crude extracts as scavengers of superoxide radicals and inhibitors of xanthine oxidase,” Planta Medica, vol. 58, no. 4, pp. 342–344, 1992.View at: Publisher Site | Google Scholar
22. P. Cos, L. Ying, M. Calomme et al., “Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers,” Journal of Natural Products, vol. 61, no. 1, pp. 71–76, 1998.
23. D. E. C. van Hoorn, R. J. Nijveldt, P. A. M. van Leeuwen, et al., "Accurate prediction of xanthine oxidase inhibition based on the structure of flavonoids," European Journal of Pharmacology, vol. 451, no. 2, pp. 111–118, 2002.
24. R. Arimboor, M. Rangan, S. G. Aravind, and C. Arumughan, “Tetrahydroamentoflavone (THA) from Semecarpus anacardium as a potent inhibitor of xanthine oxidase,” Journal of Ethnopharmacology, vol. 133, no. 3, pp. 1117–1120, 2011.
25. Cherkaoui S, Bekkouche K, Christen P, Veuthey JL. Nonaqueous capillary electrophoresis with diode array and electrospray mass spectrometric detection for the analysis of selected steroidal alkaloids in plant extracts. J Chromatogr A 2001; 922(1-2): 321-328.
26. Crawford L, Myhr B. A preliminary assessment of the toxic and mutagenic potential of steroidal
27. F. Candan, “Effect of Rhus coriaria L. (Anacardiaceae) on superoxide radical scavenging and xanthine oxidase activity,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 18, no. 1, pp. 59–62, 2003.
28. A. Mittal, A. R. J. Phillips, B. Loveday, and J. A. Windsor, “The potential role for xanthine oxidase inhibition in major intraabdominal surgery,” World Journal of Surgery, vol. 32, no. 2, pp. 288–295, 2008.
29. P. Cos, L. Ying, M. Calomme et al., “Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers,” Journal of Natural Products, vol. 61, no. 1, pp. 71–76, 1998.
30. Dawson and M. Walters, “Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?” British Journal of Clinical Pharmacology, vol. 62, no. 6, pp. 633–644, 2006.
31. H. K. Choi, D. B. Mount, and A. M. Reginato, “Pathogenesis of gout,” Annals of Internal Medicine, vol. 143, no. 7, pp. 499–516, 2005
32. F. J. Nieto, C. Iribarren, M. D. Gross, G. W. Comstock, and R. G. Cutler, “Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?” Atherosclerosis, vol. 148, no. 1, pp. 131–139, 2000.
33. A. Burke, E. Smyth, and G. A. FitzGerald, “Analgesic– antipyretic agents; pharmacotherapy of gout,” in The Pharmacological Basis of Therapeutics, L. L. Brunton, J. S. Lazo, and K. L. Parker, Eds., pp. 706–710, McGraw-Hill Medical Publishing Division, New York, NY, USA, 11th edition, 2006.
34. J. F. Baker, E. Krishnan, L. Chen, and H. R. Schumacher, “Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?” The American Journal of Medicine, vol. 118, no. 8, pp. 816–826, 2005.
35. S. Kivity, E. Kopel, E. Maor et al., “Association of serum uric acid and cardiovascular disease in healthy adults,”The American Journal of Cardiology, vol. 111, no. 8, pp. 1146–1151, 2013.
36. S. G. Wannamethee, “Serum uric acid and risk of coronary heart disease,” Current Pharmaceutical Design, vol. 11, no. 32, pp. 4125–4132, 2005.
37. E. J. Newman, F. S. Rahman, K. R. Lees, C. J. Weir, and M. R. Walters, “Elevated serum urate concentration independently predicts poor outcome following stroke in patients with diabetes,” Diabetes/Metabolism Research and Reviews, vol. 22, no. 1, pp. 79–82, 2006.
38. Danijela A. KostiT, Danica S. DimitrijeviT, Gordana S. StojanoviT, Ivan R. PaliT, Aleksandra S. YorZeviT, and Jovana D. Ickovski, ‘’Xanthine Oxidase: Isolation, Assays of Activity, and Inhibition,’’ Journal of Chemistry, Volume 2015 |Article ID 294858 | https://doi.org/10.1155/2015/294858
39. T. M. Ngoc, N. M. Khoi, D. T. Ha et al., “Xanthine oxidase inhibitory activity of constituents of Cinnamomum cassia twigs,” Bioorganic and Medicinal Chemistry Letters, vol. 22, no. 14, pp. 4625–4628, 2012.
40. T. Unno, A. Sugimoto, and T. Kakuda, “Xanthine oxidase inhibitors from the leaves of Lagerstroemia speciosa (L.) Pers,” Journal of Ethnopharmacology, vol. 93, no. 2-3, pp. 391–395, 2004.
41. M. Umamaheswari, K. Asokkumar, A. T. Sivashanmugam, A. Remyaraju, V. Subhadradevi, and T. K. Ravi, “In vitro xanthine oxidase inhibitory activity of the fractions of Erythrina stricta Roxb.,” Journal of Ethnopharmacology, vol. 124, no. 3, pp. 646– 648, 2009.
42. Parida P, Yadav RN, Shankar BR, Chakraborty DI, Das A and Singh NK: In-silico protein ligand interaction study of typical antipsychotic drugs against dopaminergic D2 receptor. Int J Phar Pharmceusci 2012; 5: 183-9.